Catabasis Pharmaceuticals Appoints Joanne T. Beck to its Board of Directors

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis
Pharmaceuticals, Inc.
(NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced the appointment of Joanne T.
Beck, Ph.D., to its Board of Directors. Dr. Beck has more than 25 years
of pharmaceutical development and operations experience and is currently
the Executive Vice President, Global Pharmaceutical Development and
Operations at Celgene. She has joined the Board as Michael Ross,
co-Chairman, steps down from Catabasis’ Board of Directors.

Joanne brings deep knowledge of pharmaceutical development and
operations to Catabasis, and we are excited to have her join our board
of directors,” said Ken Bate, Chairman of Catabasis’ Board of Directors.
Her leadership experience and knowledge of rare disease pharmaceutical
development is a significant asset to the organization as we continue
NDA-enabling activities and begin initial preparations for the potential
commercial launch of edasalonexent following the completion of the
current Phase 3 trial in Duchenne muscular dystrophy. On behalf of the
Board and the executive team at Catabasis, I also want to extend my
gratitude to Mike Ross for his tremendous leadership and contributions
over the past eight years. He has played a critical role in the
development of Catabasis and in support of our mission.”

I am thrilled to have the opportunity to support Catabasis as the
organization prepares to bring forward a potential new therapy that
could benefit all affected by Duchenne,” said Dr. Beck. “I see great
potential for edasalonexent to change the treatment paradigm for
Duchenne, and I am honored to be part of this organization and its
relentless commitment to improving the lives of those affected by this
devastating disease.”

Dr. Beck currently serves on the Board of Directors of Orchard
Therapeutics and the Alliance for Regenerative Medicine. Prior to
Celgene, Dr. Beck was at Shire and served as Senior Vice President,
Pharmaceutical Development from 2014 to 2016 as well as Vice President,
Process Development and Manufacturing Sciences from 2012 to 2014. Dr.
Beck holds a Bachelor of Arts from Lewis and Clark College (Portland,
OR), a Ph.D. in Biochemistry and Molecular Biology from Oregon Health
and Science University (Portland, OR) and completed a postdoctoral
fellowship in the department of Pharmaceutical Chemistry at the
University of California, San Francisco.

About Catabasis

At Catabasis Pharmaceuticals, our mission is to bring hope and
life-changing therapies to patients and their families. Our lead program
is edasalonexent, an NF-kB inhibitor in development for the treatment of
Duchenne muscular dystrophy. Our global Phase 3 PolarisDMD trial is
currently enrolling boys affected by Duchenne. For more information on
edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com
or www.twitter.com/catabasispharma.

Forward Looking Statements

Any statements in this press release about future expectations, plans
and prospects for the Company, including statements about the potential
commercial launch of edasalonexent, and other statements containing the
words “believes,” “anticipates,” “plans,” “expects,” “may” and similar
expressions, constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including:
uncertainties inherent in the initiation and completion of preclinical
studies and clinical trials and clinical development of the Company’s
product candidates; whether interim results from a clinical trial will
be predictive of the final results of the trial or the results of future
trials; expectations for regulatory approvals to conduct trials or to
market products; availability of funding sufficient for the Company’s
foreseeable and unforeseeable operating expenses and capital expenditure
requirements; other matters that could affect the availability or
commercial potential of the Company’s product candidates; and general
economic and market conditions and other factors discussed in the “Risk
Factors” section of the Company’s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2018, which is on file with the Securities
and Exchange Commission, and in other filings that the Company may make
with the Securities and Exchange Commission in the future. In addition,
the forward-looking statements included in this press release represent
the Company’s views as of the date of this press release. The Company
anticipates that subsequent events and developments will cause the
Company’s views to change. However, while the Company may elect to
update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the
Company’s views as of any date subsequent to the date of this release.

Contacts

Investors and Media
Andrea Matthews
Catabasis
Pharmaceuticals, Inc.
T: (617) 349-1971
amatthews@catabasis.com

error: Content is protected !!